Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2

Q Medicine

Clinical Lipidology Pub Date : 2017-01-01 DOI:10.1080/17584299.2017.1383700

S. Iyengar, R. Puri, S. Narasingan, D. Nair, V. Mehta, J. Mohan, S. Wangnoo, J. Dalal, V. Jha, S. Puri, A. Misra, M. Daga, M. Varma, S. Jasuja, S. Upadhyaya, R. Kasliwal, M. Bansal, R. Mehrotra, A. Jain, K. K. Talwar, R. Rajput, A. Pradhan, S. Seth, D. Kapoor, R. Melinkeri, S. Ramakrishnan, N. Khanna, R. Khadgawat, S. Puri, A. Shaikh, N. Kovalipati, N. Bordoloi, A. Zargar, R. Agarwal, A. Rastogi, M. Chag, D. Prabhakar, S. Mathur, H. Rehan, P. Sahoo, A. Dutta, A. Sharma, A. Pancholia, K. Natarajan, A. Mishra, K. Singh

{"title":"Lipid Association of India (LAI) expert consensus statement on management of dyslipidaemia in Indians 2017: part 2","authors":"S. Iyengar, R. Puri, S. Narasingan, D. Nair, V. Mehta, J. Mohan, S. Wangnoo, J. Dalal, V. Jha, S. Puri, A. Misra, M. Daga, M. Varma, S. Jasuja, S. Upadhyaya, R. Kasliwal, M. Bansal, R. Mehrotra, A. Jain, K. K. Talwar, R. Rajput, A. Pradhan, S. Seth, D. Kapoor, R. Melinkeri, S. Ramakrishnan, N. Khanna, R. Khadgawat, S. Puri, A. Shaikh, N. Kovalipati, N. Bordoloi, A. Zargar, R. Agarwal, A. Rastogi, M. Chag, D. Prabhakar, S. Mathur, H. Rehan, P. Sahoo, A. Dutta, A. Sharma, A. Pancholia, K. Natarajan, A. Mishra, K. Singh","doi":"10.1080/17584299.2017.1383700","DOIUrl":null,"url":null,"abstract":"ABSTRACT These Lipid Association of India (LAI) recommendations refer to specific patient populations. They follow the previously published LAI part 1 recommendations. These part 2 LAI recommendations focus on specific patient groups. These include patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection. We also consider women, the elderly and post-transplantation patients. The current recommendations are based, as much as possible, on available data from Indian populations.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"2 1","pages":"109 - 56"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17584299.2017.1383700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 13

Abstract

ABSTRACT These Lipid Association of India (LAI) recommendations refer to specific patient populations. They follow the previously published LAI part 1 recommendations. These part 2 LAI recommendations focus on specific patient groups. These include patients with heart failure, chronic kidney disease, non-alcoholic fatty liver disease, cerebrovascular disease, thyroid disorders, inflammatory joint diseases, familial hypercholesterolaemia and human immunodeficiency virus infection. We also consider women, the elderly and post-transplantation patients. The current recommendations are based, as much as possible, on available data from Indian populations.

查看原文本刊更多论文

印度脂质协会(LAI) 2017年印度人血脂异常管理专家共识声明:第2部分

这些脂质协会印度(LAI)的建议是针对特定的患者群体。它们遵循先前发布的LAI第1部分建议。这些第2部分的LAI建议侧重于特定的患者群体。这些患者包括心力衰竭、慢性肾病、非酒精性脂肪性肝病、脑血管疾病、甲状腺疾病、炎症性关节疾病、家族性高胆固醇血症和人类免疫缺陷病毒感染。我们也考虑妇女、老年人和移植后患者。目前的建议尽可能多地基于印度人口的现有数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lipidology 生物-生化与分子生物学

CiteScore

0.44

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.